See more : Reliance Chemotex Industries Limited (RELCHEMQ.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Elevation Oncology, Inc. (ELEV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevation Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rio Tinto Group (RIO.BA) Income Statement Analysis – Financial Results
- Novozymes A/S (NSIS-B.CO) Income Statement Analysis – Financial Results
- Atkore Inc. (ATKR) Income Statement Analysis – Financial Results
- Capstone Technologies Group, Inc. (CATG) Income Statement Analysis – Financial Results
- Anatara Lifesciences Ltd (ANR.AX) Income Statement Analysis – Financial Results
Elevation Oncology, Inc. (ELEV)
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.00K | 27.00K | 18.00K | 15.00K | 0.00 |
| Gross Profit | -39.00K | -27.00K | -18.00K | -15.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.43M | 78.72M | 23.60M | 15.48M | 5.34M |
| General & Administrative | 14.90M | 15.83M | 8.45M | 1.80M | 816.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 543.18K |
| SG&A | 14.90M | 15.83M | 8.45M | 1.80M | 544.00K |
| Other Expenses | 5.11M | -506.00K | 7.00K | 11.00K | 0.00 |
| Operating Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Cost & Expenses | 45.45M | 94.55M | 32.05M | 17.28M | 5.88M |
| Interest Income | 3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 479.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.00K | 27.00K | 18.00K | 15.00K | 3.57M |
| EBITDA | -41.47M | -94.52M | -32.03M | -17.25M | -5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.45M | -94.55M | -32.05M | -17.28M | -5.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -229.00K | -506.00K | 7.00K | 11.00K | 0.00 |
| Income Before Tax | -45.67M | -95.06M | -32.04M | -17.27M | -5.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 25.00K | -218.56K | -191.30K | -8.82K |
| Net Income | -45.70M | -95.08M | -32.04M | -17.27M | -5.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| EPS Diluted | -1.34 | -4.09 | -1.38 | -0.73 | -0.25 |
| Weighted Avg Shares Out | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
| Weighted Avg Shares Out (Dil) | 34.08M | 23.27M | 23.21M | 23.76M | 23.76M |
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
NEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs,...
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Closed underwritten...
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
NEW YORK , July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical...
Why Is Elevation Oncology (ELEV) Stock Down 26% Today?
Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public offering of ELEV stock has the company selling 17,810,000 shares at a price of $2.25 each.
Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology
Elevation Oncology NASDAQ: ELEV is a biotech company that focuses on discovering and developing cancer therapies. The company aims to treat patients with various solid tumors with significant unmet medical needs.
Why Is Elevation Oncology (ELEV) Stock Up 57% Today?
Elevation Oncology (NASDAQ: ELEV ) stock is on the rise Friday despite a lack of news from the pharmaceutical company. There's no news that explains why shares of ELEV stock are taking off today.
5 Penny Stocks To Watch Before Next Week; Time To Buy?
If you're like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum.
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
Source: https://incomestatements.info
Category: Stock Reports